Telum Therapeutics
Agent50Agent Readiness: 50/100. Top 25%. Measured by StartupHub.ai. Median 41.Biotechnology company developing novel protein-based antimicrobial therapeutics.
About
Telum Therapeutics is a Spanish biotechnology company focused on developing a new class of antimicrobial therapies to combat difficult-to-treat infections, particularly hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Their lead program targets Acinetobacter baumannii, a multidrug-resistant pathogen. The company's proprietary APEX platform is designed to create biologically derived, protein-based therapeutics that aim to overcome the limitations of existing antibiotics.
Key facts
At-a-glance profile data
- Website
- telumtherapeutics.com
- Headquarters
- Navarra, Spain
- Founded
- 2019
- Total funding
- $21M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Jul 2026 | Series A | $18M | AMR Action Fund |
| 1 Mar 2022 | Seed | $3M | Inveready, Clave Capital |
Tech stack
Detected on telumtherapeutics.com, last scanned 29 Aug 2026. Run your own scan
- Hosting
- Google Cloud
Frequently asked
How much funding has Telum Therapeutics raised?
Telum Therapeutics has raised a total of $21M in funding. The most recent round on record is Series A.
What is Telum Therapeutics's current status?
Telum Therapeutics's current operating status is: Inactive.